富国久利稳健配置A

Search documents
近一个月超百只基金限购
Di Yi Cai Jing Zi Xun· 2025-08-12 05:14
Core Insights - Recent fund purchases have been limited to 100,000 yuan per day, indicating a trend of restricting large inflows into high-performing funds as the A-share market rebounds and the Shanghai Composite Index reaches new highs [2][3] - Over 133 funds have announced restrictions on large purchases in the past month, primarily those with outstanding performance and rapid growth in scale [3] - The proactive limitation of fund sizes is seen as a measure to ensure the effectiveness of investment strategies and stabilize fund operations, while also cooling down excessive market enthusiasm [2][5] Fund Performance and Restrictions - The China Europe Medical Innovation fund, managed by renowned fund manager Ge Lan, has implemented a purchase limit of 100,000 yuan starting August 11, marking its first restriction since October 2019 [3] - Among the actively managed equity funds currently under purchase restrictions, 211 out of 214 have achieved positive returns over the past year, with over 40% of them yielding returns exceeding 30% [3][4] - The China Europe Digital Economy fund has seen a staggering increase in scale from 12.38 million yuan to 1.527 billion yuan within a year, representing a growth of over 122 times [4] Market Dynamics - The A-share market has shown a strong upward trend, with the Shanghai Composite Index reaching 3,656.85 points on August 11, marking a new high for the year [6] - The influx of individual investors has been a significant driver of market momentum, with 14.56 million new accounts opened this year, a 36.9% increase year-on-year [6] - The market's valuation remains relatively low compared to overseas markets, suggesting potential for further expansion [6] Future Outlook - Analysts predict that the current market may be entering a later stage of the rally, with potential for horizontal adjustments in the short term [7] - The focus will be on the upcoming earnings reports and policy details in September, which could validate the ongoing trends in the market [7][8] - The innovation drug sector is expected to transition into a phase where actual performance will be tested, with companies that can secure good partnerships likely to stand out [8]
近一个月超百只基金限购
第一财经· 2025-08-12 05:04
Core Viewpoint - The recent trend of limiting large fund subscriptions in the A-share market is a response to the strong performance of certain funds, aiming to manage inflows and maintain investment strategy effectiveness [3][5][7]. Group 1: Fund Performance and Subscription Limits - A significant number of funds, over 133, have announced restrictions on large subscriptions, particularly those with outstanding performance and rapid growth in scale [5][6]. - Among actively managed equity funds currently under subscription limits, 214 funds have achieved positive returns over the past year, with over 40% of them yielding returns exceeding 30% [5][6]. - The fund "China Europe Digital Economy A" leads with a return of 146.87% and has recently suspended large subscriptions over 100 million yuan [5][6]. Group 2: Market Dynamics and Investor Behavior - The A-share market has shown a strong upward trend, with the Shanghai Composite Index reaching a new high of 3656.85 points, supported by increased retail investor participation [9][10]. - The number of new A-share accounts opened this year has reached 14.56 million, a 36.9% increase year-on-year, indicating a robust influx of retail capital [9][10]. - Fund companies are limiting subscriptions to prevent investors from making impulsive decisions based on short-term performance, promoting a more rational investment approach [7][10]. Group 3: Future Market Outlook - Analysts suggest that while the current market momentum is strong, there may be a need for short-term adjustments, with potential volatility expected [10]. - The market is seen as being in a liquidity-driven phase, with opportunities arising from structural changes in the economy [10][11]. - The innovative pharmaceutical sector is highlighted as a key area for future growth, with expectations for continued performance improvements in related companies [11].
近一个月超百只基金限购,业绩高增为何主动“踩刹车”?
Di Yi Cai Jing· 2025-08-11 11:33
Group 1 - The recent trend of limiting large subscriptions for high-performing funds is a response to the A-share market's recovery, with the Shanghai Composite Index stabilizing above 3600 points and reaching a year-to-date high [1][2] - As of August 11, over 133 funds have announced the suspension of large subscriptions, primarily those with outstanding performance and rapid growth in scale, with more than 40% of active equity funds achieving returns over 30% in the past year [2][3] - The proactive limitation of fund sizes is seen as a prudent measure to ensure the effectiveness of investment strategies and the stability of fund operations, while also cooling down excessive market enthusiasm [1][4] Group 2 - The fund "China Europe Medical Innovation," managed by renowned fund manager Ge Lan, has implemented a daily subscription limit of 100,000 yuan, marking a significant reduction from previous limits [2][3] - The rapid growth of fund sizes is evident, with some funds experiencing increases of over 10 times, such as Hai Fu Tong Quantitative Vanguard A and Guo Fu Zhao Rui You Xuan A, which had sizes below 60 million yuan at the end of last year [3][4] - The current market dynamics are supported by a surge in individual investor participation, with 14.56 million new accounts opened this year, a 36.9% increase year-on-year, and a significant rise in financing balances [6][7] Group 3 - The A-share market is expected to continue its upward trend, with liquidity support remaining strong, although there may be short-term adjustments due to market conditions [6][7] - The innovation drug sector is transitioning into a phase where actual performance will be tested, with companies that can secure good business development collaborations likely to stand out [8] - Attention is drawn to sectors with improving performance, such as orthopedic and innovative drug upstream companies, as well as medical devices, which may present investment opportunities [8]
固收+爆火,年内业绩怎样?业绩首尾差近20%,融通、汇丰晋信、金鹰基金旗下产品垫底
Sou Hu Cai Jing· 2025-05-28 11:46
| 基金名称 | 今年以来收益率(%) | 规模(亿) | 成立年限 | 其全经理 | 今年以来最大回撤(%) | | --- | --- | --- | --- | --- | --- | | 工银聚享A | 13.65 | 0.42 | 3.76 | 何顺,焦文龙 | -4.90 | | 富国久利稳健配置A | 12.20 | 2.39 | 8.42 | 蔡耀华,刘兴旺 | -11.55 | | 格林鑫利六个月持有A | 8.98 | 0.18 | 2.19 | 刘赞,索隽石 | -3.55 | | 兴全汇吉一年持有A | 8.61 | 10.50 | 4.30 | 刘琦 | -2.28 | | 华商恒益稳健 | 7.49 | 2.97 | 5.27 | 张晓 | -4.51 | | 平安瑞尚六个月持有A | 7.45 | 0.90 | 4.44 | 启漫 | -3.76 | | 淳厚利加A | 6.25 | 0.01 | 2.83 | 江文军,翟羽佳 | -7.86 | | 鹏华安和A | 6.13 | 1.88 | 4.95 | 汤志彦 | -4.53 | | 中银顺兴回报 - 年持有A | ਟ.99 ...